Agenus Inc. (AGEN) Sees Large Volume Increase
Agenus Inc. (NASDAQ:AGEN) shares saw an uptick in trading volume on Thursday . 1,026,970 shares traded hands during mid-day trading, an increase of 5% from the previous session’s volume of 982,088 shares.The stock last traded at $4.65 and had previously closed at $4.46.
Several brokerages have recently commented on AGEN. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Tuesday. Maxim Group reiterated a “buy” rating and issued a $7.00 target price on shares of Agenus in a research report on Friday, June 10th. JPMorgan Chase & Co. decreased their target price on Agenus from $17.00 to $15.00 and set a “market outperform” rating for the company in a research report on Wednesday, March 9th. JMP Securities decreased their target price on Agenus from $17.00 to $15.00 and set a “market outperform” rating for the company in a research report on Wednesday, March 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Agenus in a research report on Saturday, April 30th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.47.
The firm’s 50 day moving average is $4.08 and its 200 day moving average is $3.78. The firm’s market cap is $407.48 million.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, April 28th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.14. On average, analysts expect that Agenus Inc. will post ($1.41) earnings per share for the current fiscal year.
In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was acquired at an average price of $3.18 per share, with a total value of $318,000.00. Following the transaction, the chief executive officer now owns 1,346,026 shares of the company’s stock, valued at $4,280,362.68. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
A hedge fund recently raised its stake in Agenus stock. Wells Fargo & Company MN boosted its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 177.2% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 332,554 shares of the company’s stock after buying an additional 212,599 shares during the period. Wells Fargo & Company MN owned approximately 0.39% of Agenus worth $1,510,000 at the end of the most recent quarter.
Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).